) recently announced that its triple combination hypertension pill
Rasitrio has been cleared in the European Union (
). Rasitrio combines the currently marketed hypertension pill
Razilez (marketed as Tekturna in the US) with amlodipine and
hydrochlorothiazide (HCT). The pill is already marketed as
Amturnide in the US.
The approval of Rasitrio was based on data from late stage
trials which showed that the drug significantly reduced blood
pressure as compared to dual combinations of each of its individual
components. The positive effect of Rasitrio was seen within a week
of starting treatment and was maintained for the entire 24-hour
dose interval. The approval of Rasitrio is a definite boon for
sufferers of hypertension as most (almost 85%) have to recourse to
multiple medicines to control their blood pressure.
Novartis markets other hypertension combination pills like
Tekturna HCT, Valturna, and Tekamlo. Tekturna HCT is a single-pill
combination of Tekturna and HCT which is marketed in the US and EU
(as Rasilez HCT). Valturna, a single-pill combination of Tekturna
and Diovan, is marketed in the US. Tekamlo is a single-pill
combination of Tekturna and amlodipine, also marketed in the US and
EU (as Rasilamlo).
Currently, we have a Neutral recommendation on Novartis. The
company carries a Zacks #3 Rank ("Hold" rating) in the short run.
Though pleased with Novartis' wide range of products and its
efforts to diversify further, as is evident by the acquisition of
eye-care company Alcon, we prefer to remain on the sidelines due to
the imminent patent cliff faced by the company.
NOVARTIS AG-ADR (
): Free Stock Analysis Report